It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARQT’s FA Score shows that 0 FA rating(s) are green whilePVLA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARQT’s TA Score shows that 4 TA indicator(s) are bullish while PVLA’s TA Score has 4 bullish TA indicator(s).
ARQT (@Biotechnology) experienced а -4.24% price change this week, while PVLA (@Biotechnology) price change was -9.02% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.
ARQT is expected to report earnings on Oct 29, 2026.
PVLA is expected to report earnings on Nov 17, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ARQT | PVLA | ARQT / PVLA | |
| Capitalization | 3.15B | 2.05B | 154% |
| EBITDA | 14.3M | -42.66M | -34% |
| Gain YTD | -13.636 | 35.703 | -38% |
| P/E Ratio | 114.00 | 14.22 | 802% |
| Revenue | 416M | 0 | - |
| Total Cash | 224M | 262M | 85% |
| Total Debt | 115M | 584K | 19,692% |
ARQT | PVLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 90 | 98 | |
PRICE GROWTH RATING 1..100 | 48 | 37 | |
P/E GROWTH RATING 1..100 | 53 | 11 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PVLA's Valuation (74) in the null industry is in the same range as ARQT (94). This means that PVLA’s stock grew similarly to ARQT’s over the last 12 months.
ARQT's Profit vs Risk Rating (95) in the null industry is in the same range as PVLA (100). This means that ARQT’s stock grew similarly to PVLA’s over the last 12 months.
ARQT's SMR Rating (90) in the null industry is in the same range as PVLA (98). This means that ARQT’s stock grew similarly to PVLA’s over the last 12 months.
PVLA's Price Growth Rating (37) in the null industry is in the same range as ARQT (48). This means that PVLA’s stock grew similarly to ARQT’s over the last 12 months.
PVLA's P/E Growth Rating (11) in the null industry is somewhat better than the same rating for ARQT (53). This means that PVLA’s stock grew somewhat faster than ARQT’s over the last 12 months.
| ARQT | PVLA | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 89% | 3 days ago 79% |
| Momentum ODDS (%) | 3 days ago 81% | 3 days ago 85% |
| MACD ODDS (%) | N/A | 3 days ago 89% |
| TrendWeek ODDS (%) | 3 days ago 85% | 3 days ago 86% |
| TrendMonth ODDS (%) | 3 days ago 86% | 3 days ago 88% |
| Advances ODDS (%) | 12 days ago 86% | 11 days ago 84% |
| Declines ODDS (%) | 3 days ago 87% | 3 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 90% | N/A |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| APHU | 23.50 | 1.12 | +5.02% |
| T-REX 2x Long Aph Daily Target ETF | |||
| BOTZ | 36.04 | 0.23 | +0.64% |
| Global X Robotics & Artfcl Intllgnc ETF | |||
| CGO | 13.15 | 0.02 | +0.15% |
| Calamos Global Total Return Fund | |||
| BUCK | 23.42 | -0.05 | -0.21% |
| Simplify Treasury Option Income ETF | |||
| SARK | 24.77 | -0.95 | -3.70% |
| Tradr 1X Short Innovation Daily ETF | |||
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | -1.07% | ||
| XNCR - ARQT | 43% Loosely correlated | +2.96% | ||
| TGTX - ARQT | 39% Loosely correlated | +7.34% | ||
| PVLA - ARQT | 39% Loosely correlated | -0.38% | ||
| TRDA - ARQT | 38% Loosely correlated | -0.39% | ||
| PTCT - ARQT | 38% Loosely correlated | -0.99% | ||
More | ||||
A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To PVLA | 1D Price Change % | ||
|---|---|---|---|---|
| PVLA | 100% | -0.38% | ||
| VIR - PVLA | 44% Loosely correlated | +6.19% | ||
| DRMA - PVLA | 42% Loosely correlated | +2.90% | ||
| TRVI - PVLA | 40% Loosely correlated | -1.59% | ||
| ARQT - PVLA | 38% Loosely correlated | -1.07% | ||
| BEAM - PVLA | 37% Loosely correlated | +4.83% | ||
More | ||||